Intermediate-Term Oncologic Outcome Assessment for Robot-Assisted Radical Prostatectomy: Comparing Retzius-Sparing...

Area of Science:

• Urology
• Oncology
• Surgical Innovation

Background:

• Retzius-sparing prostatectomy is increasingly adopted, often linked to improved early continence.
• However, long-term oncologic outcomes compared to standard techniques remain less understood.
• This study evaluates intermediate-term oncologic results from a randomized trial.

Purpose of the Study:

• To compare the intermediate-term oncologic outcomes of Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) versus standard robot-assisted radical prostatectomy (S-RARP).
• To assess differences in biochemical recurrence (BCR) and survival rates between the two surgical approaches.

Main Methods:

• A randomized controlled trial comparing RS-RARP and S-RARP in 120 patients.
• Data collection included baseline, surgical, pathological characteristics, and oncologic outcomes.
• Median follow-up was approximately 71 months.

Main Results:

• No significant differences in baseline or surgical characteristics were observed.
• Higher rates of pathologic T3 disease were noted in the RS-RARP group.
• No statistically significant difference in positive margin status or biochemical recurrence (BCR) rates was found between groups.
• Five-year BCR-free survival was 91% for S-RARP and 85% for RS-RARP (p=0.21).

Conclusions:

• Retzius-sparing and standard robot-assisted radical prostatectomy demonstrate comparable intermediate-term oncologic outcomes.
• Biochemical recurrence rates were similar between the two techniques.
• Larger, multi-institutional studies with longer follow-up are needed to confirm these findings.